Certified by Founder
Lodge
XyloCor Therapeutics, Inc.
start up
United States
- King of Prussia, Pennsylvania
- 09/01/2025
- Series B
- $67,500,000
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.
- Industry Research Services
- Website https://www.xylocor.com/
- LinkedIn https://www.linkedin.com/company/xylocor-therapeutics-inc./
Forage | $40,000,000 | (Jun 5, 2026)
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
ZutaCore | $100,000,000 | (Jun 5, 2026)
Terra AI | $20,000,000 | (Jun 5, 2026)
Town | $55,000,000 | (Jun 5, 2026)
Lassie | $35,000,000 | (Jun 5, 2026)
OFFROAD | $7,000,000 | (Jun 5, 2026)
Shifters | $10,200,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Scispot | $8,000,000 | (Jun 5, 2026)
Scotch | $20,000,000 | (Jun 5, 2026)